pdufa.bio
Home › Decisions › REGN 2026-04-23

REGN FDA decision: Apr 23, 2026

Page updated ·next FDA decision on the calendar ·Data as of Oct 11, 2026 9:31 PM ET
✓ APPROVED

Otarmeni (lunsotogene parvec-cwha) was approved by the FDA for sensorineural hearing loss; the approval was announced on April 23, 2026.

Regeneron Pharmaceuticals Inc., Otarmeni (lunsotogene parvec-cwha) · Sensorineural hearing loss.

Run-up into the decision (T-120 → T+5)

PDUFA 4/23/26$812.27$62811/6/25
Daily close, T-120 (11/6/25) through T+5. Run-up high $812.27 on 1/12/26, low $628 on 11/12/25 (T-120 to T-1). FDA decision 4/23/26. Historical price action, not a forecast.

Key facts

FDA decision date2026-04-23
OutcomeApproved
Drug / candidateOtarmeni (lunsotogene parvec-cwha)
CompanyRegeneron Pharmaceuticals Inc.
120-day run-up (T-120→T-1)+14.3%

Every FDA approval letter and released Complete Response Letter we hold, by FDA action date: FDA approval letters.

Questions

Was Otarmeni (lunsotogene parvec-cwha) approved by the FDA?

Yes. The approval of the application for Otarmeni (lunsotogene parvec-cwha) was announced on April 23, 2026; pdufa.bio holds no FDA record stating the exact day the FDA acted. The primary source is linked on this page.

Which company is behind Otarmeni (lunsotogene parvec-cwha)?

Otarmeni (lunsotogene parvec-cwha) is a Regeneron Pharmaceuticals Inc. (REGN) program. The company announced the FDA decision on April 23, 2026; the primary source is linked on this page.

How did REGN stock trade into the FDA decision?

Measured over the 120 trading days before the decision (T-120 to T-1), REGN moved +14.3%. That is the recorded price path into this specific event. Historical measurement, not a prediction, and not investment advice.